MACD: Histogram at -0.00369 and negatively expanding → bearish momentum strengthening, not stabilizing.
RSI(6): 21.63 (deeply weak/near oversold). This can enable a short bounce, but by itself is not a buy trigger in a strong downtrend.
Key levels: Price ~0.2326 is sitting on S1 (0.232). A break below S1 increases odds of a move toward S2 (0.21). Upside resistance sits at Pivot 0.266 then R1 0.30.
Pattern-based outlook provided: suggests elevated short-term volatility (reported 60% chance of a strong weekly move), but the current indicators favor downside continuation unless price reclaims the pivot area (~0.266).
Positive Catalysts
Oversold/washed-out RSI may fuel a reflex bounce if support at ~0.232 holds.
If price reclaims and holds above the pivot (~0.266), it could trigger a technical mean-reversion move toward 0.30.
Neutral/Negative Catalysts
worsening MACD momentum imply sellers remain in control.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no improvement; effectively no operating scale shown).
Net income: -2.76M (less negative YoY, but still meaningfully loss-making).
EPS: -0.67, down YoY (worse per-share performance despite net loss improvement).
Gross margin: 0, down YoY (weak/absent gross profitability signal).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating / price target change data provided, so there is no clear read-through on Wall Street’s current pro vs. con stance.
With no recent published rating/target trend in the dataset, the decision must rely primarily on the bearish technicals and weak operating profile shown.
Wall Street analysts forecast AZTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast AZTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 0.209
Low
0
Averages
0
High
0
0
Current: 0.209
Low
0
Averages
0
High
0
Maxim
Buy
downgrade
$4
AI Analysis
2025-09-24
Reason
Maxim
Price Target
$4
AI Analysis
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Azitra to $4 from split-adjusted $13.32 and keeps a Buy rating on the shares. The firm is citing its expectations of dilution in cutting its price target as the company addresses capital needs to advance ATR-12 and ATR-04 forward in clinical development, the analyst tells investors in a research note. Maxim adds however that Azitra's lead program ATR-12 in Netherton syndrome reported positive initial safety data in June, and if positive, its ongoing Phase 1 trial could be a key catalyst for shares.
